Indirubin inhibits cell proliferation, migration, invasion and angiogenesis in tumor-derived endothelial cells.

Abstract

PURPOSE:

Hepatocellular carcinoma is one of the most predominant malignancies with high fatality rate and its incidence is rising at an alarming rate because of its resistance to radio- and chemotherapy. Indirubin is the major active anti-tumor ingredient of a traditional Chinese herbal medicine. The present study aimed to analyze the effects of indirubin on cell proliferation, migration, invasion, and angiogenesis of tumor-derived endothelial cells (Td-EC).

METHODS:

Td-EC were derived from human umbilical vein endothelial cells (HUVEC) by treating HUVEC with the conditioned medium of human liver cancer cell line HepG2. Cell proliferation, migration, invasion, and angiogenesis were assessed by MTT, wound healing, in vitro cell invasion, and in vitro tube formation assay.

RESULTS:

Td-EC were successfully obtained from HUVEC cultured with 50% culture supernatant from serum-starved HepG2 cells. Indirubin significantly inhibited Td-EC proliferation in a dose- and time-dependent manner. Indirubin also inhibited Td-EC migration, invasion, and angiogenesis. However, indirubin's effects were weaker on HUVEC than Td-EC.

CONCLUSION:

Indirubin significantly inhibited Td-EC proliferation, migration, invasion, and angiogenesis.

• Authors: Zhuohong Li, Chaofu Zhu, Baiping An, Yu Chen, Xiuyun He, Lin Qian, Lan Lan, Shijie Li
• Journal: OncoTargets and therapy (Onco Targets Ther) Vol. 11 Pg. 2937-2944 ( 2018) ISSN: 1178-6930 [Print] New Zealand
• PMID: 29849463 (Publication Type: Journal Article)